Top stories about the VC industry, Alumni Ventures, and your investments.
Why the Potential of Superconductors Could Create Significant Investment OpportunitiesThe potential of superconductor technology has introduced the world to what could eventually become one of the breakthrough technological discoveries in human history, easily on par with the discovery of electricity, steam power, and generative artificial intelligence. It certainly has the attention of VCs, who immediately grasped how this transformative tech could fundamentally reshape the modern economy.
- Sign Up
Last Call: Purple Arch Ventures Fund 7The deadline for Purple Arch Ventures Fund 7 is around the corner, and the team is beginning to deploy capital and build the portfolio. Join Managing Partner David Beazley, Senior Associate Rachael Ferm, Principal Lucas Pasch, and Venture Analyst Suyash Mohan to hear about some of the investments already made by Purple Arch Ventures Fund 7 and how they will continue to build a fully diversified venture portfolio.
- Sign Up
Masterclass Live! The Art of Evaluating a Venture DealRegister today for this exclusive, invite-only episode of our Masterclass Live! series with Alumni Ventures’ Chief Investment Officer Mark Edwards and Deputy CIO Andy Ervin. In this 45-minute session, you’ll discover how to evaluate a deal, walk through the process our own investment teams use to invest in promising startups, and learn how you, too, can invest in startups just like this through our Syndications Program. At Alumni Ventures, we believe everyone should have the opportunity to invest in the next big thing. That’s why we’ve created a platform that allows our investors to flex their skills by investing not only in our offerings of portfolios of startups but also in individual syndication opportunities.
Ossium Health: Streamlining Stem Cell TherapiesAlumni Ventures portfolio company Ossium Health is well-positioned to develop a leading solution in the global stem cell therapy market, projected to reach $31.4 billion by 2030. Powered by the world’s largest bone marrow donor bank, Ossium is leveraging an unprecedented amount of data on stem cell behavior and characteristics to develop therapies for blood, immune, and inflammatory diseases.
Taking a Closer Look at Alumni Ventures’ Seed FundOur Seed Fund allows accredited investors to own a diversified portfolio of ~20-30 venture-backed pre-seed and seed-stage companies — rigorously vetted and scored by our experienced teams. Each vintage features high-tech game-changers and disruptive business models from a variety of sectors and geographies.
VC 101: Why Relationships Matter in VCAccess to top deals can often be driven by who you know. Based on the science behind “six degrees of separation,” our growing network of 600,000 community members provides broad access to the entire VC universe.* In this episode of VC 101, AV Co-Founder and CCO Luke Antal discusses the importance of relationships in successful venture investments.
Scenes from Axiom Space’s Historic AX-1 MissionAV portfolio company Axiom Space became the first organization to deliver an all-private crew of astronauts to the International Space Station. Watch exclusive footage from the launch and read why our team was impressed by Axiom’s technical innovations, highly experienced flight team, and strong conviction from investors.
- Sign Up
An Introduction to Blue Ivy VenturesJoin us for a 45-minute presentation about Blue Ivy Ventures, Alumni Ventures’ Yale-focused venture capital fund. This is an excellent opportunity to meet Managing Partner, David Shaphiro and Senior Principal, Yevgeny Gelfand, and hear their approach to investing in private-stage companies.
Cohere: Democratizing Generative AI Across IndustriesAlumni Ventures’ portfolio company Cohere has developed an adaptable API that empowers companies of all sizes to enhance their workflows with NLP. The company was founded by leading AI researchers from Google and has attracted support from several established VCs and enterprise partners in the AI space.